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a  b  s  t  r  a  c  t
Early-onset  rare  diseases  have  a strong  impact  on  child  healthcare  even  though  the  incidence  of  each
of these  diseases  is  relatively  low.  In order  to  better  manage  the  care  of these  children,  it  is impera-
tive  to quickly  diagnose  the molecular  bases  for these  disorders  as  well  as  to develop  technologies  with
prognostic  potential.  Digital  PCR  (dPCR)  is  well  suited  for this  role  by providing  an absolute  quantiﬁca-
tion  of  the  target  DNA within  a  sample.  This  review  illustrates  how  dPCR  can  be  used  to identify  genes
associated  with  pediatric-onset  disorders,  to identify  copy  number  status  of  important  disease-causingeywords:
olecular diagnostics
igital PCR
roplet PCR
opy number variation
ediatrics
genes  and  variants  and  to quantify  modiﬁer  genes.  It is  also  a powerful  technology  to  track  changes  in
genomic  biomarkers  with  disease  progression.  Based  on  its  capability  to accurately  and reliably  detect
genomic  alterations  with  high  sensitivity  and  a  large  dynamic  detection  range,  dPCR  has  the  potential
to  become  the tool  of choice  for the  veriﬁcation  of  pediatric  disease-associated  mutations  identiﬁed  by
next  generation  sequencing,  copy  number  determination  and  noninvasive  prenatal  screening.
© 2016  The  Author(s).  Published  by Elsevier  GmbH.  This  is  an  open  access  article  under  the CC
endelian diseases BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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d/4.0/).1. Introduction
Genetic disorders account for about one ﬁfth of pediatric hos-
pitalizations and create an even greater burden on inpatient care
[1,2]. Even though genetic disorders are uncommon when consid-
ered individually, they affect in toto more than 20 million people
in the United States of America [3]. Additionally, it is becoming
increasingly important to accurately measure the amount of mod-
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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ﬁer genes whose copy number – like SMN2 in spinal muscular
trophy (SMA) [4] – is related to disease severity. Thus there is
 real need for a reliable, accurate and sensitive means to mea-
ure genomic variants. Most of the currently available technologies
or the identiﬁcation of disease-associated single nucleotide and
opy number variants are not sufﬁciently sensitive, not quantitative
ithout the use of external calibrator or too expensive for routine
mplementation.
Digital PCR (dPCR) provides a way for the absolute quantiﬁca-
ion of a target locus in a DNA sample. In dPCR, the target locus is
istributed across a large number of partitions by limiting dilution
o that a single DNA molecule is present in some, but not all, of the
artitions [5,6]. As a result, some of the partitions may  be devoid of
arget molecule to amplify during PCR. The abundance of the target
ocus can be measured by counting the number of partitions with a
ositive end-point reaction as well as the negative partitions. The
oisson equation ( = −ln(1 − p) where  is the average number of
olecules in the sample and p is the fraction of positive reactions)
orrects for the underestimation of the true number of molecules
y counting negative end-point reactions [7]. Because of this end-
oint measurement of abundance, dPCR does not require the use of
xternal calibration curve for calculating abundance of the target
ocus making this assay an absolute quantiﬁcation.
Early incarnations of dPCR used limiting dilution so that each
CR reaction contained a single DNA molecule. Unfortunately, this
pproach was very labor intensive and not very precise. Partition-
ng the DNA so that a single molecule would be present in a PCR
ould be a more efﬁcient approach for dPCR. dPCR currently uses
ne of two platforms to partition target DNA into very small vol-
mes: nanoﬂuidic chambers, or arrays, and nanodroplet emulsion
7]. Nanoﬂuidic arrays divide the target DNA into numerous reac-
ion chambers of nanoliter volumes wherein PCRs are run and the
umber of positive reactions is counted by ﬂuorescence imaging
8–11]. Another means of partitioning involves the emulsiﬁcation
f target DNA and PCR master mixes into thousands of nanodroplet;
he nanodroplets are counted after the PCR run for the number of
ositive reactions [12–14]. Both approaches allow for the accurate
bsolute quantiﬁcation of the target DNA in a sample.
. Applications of digital PCR to pediatric genetics
.1. Identiﬁcation of genetic alterations associated with disease
Chromosomal abnormalities involving multiple genes or whole
hromosomes have been detected historically with ﬂuores-
ence in situ hybridization (FISH) or array comparative genomic
ybridization (aCGH) panels. These approaches are labor inten-
ive and costly. Chromosomal polyploidies like trisomy 21, trisomy
8 and trisomy 13 can also be readily and easily measured with
PCR [15,16]. Droplet dPCR can also readily detect the presence of
 mosaic supernumerary marker isochromosome 12p (iso12p) in
NA samples from patients with Pallister-Killian syndrome [17].
hromosome 22q11 microdeletion syndrome, which is associated
ith neurological, cognitive and behavioral deﬁcits, can be rapidly
etected in patient DNA samples using dPCR to quantify copy
umber changes within the deleted region [18,19]. Furthermore,
PCR determines the endpoints of this deletion within chromo-
ome 22q11 [19]. Deletions within the DFNB1 locus – which include
he connexin genes GJB2 and GJB6 – can be quantitatively measured
n DNA from patients with autosomal recessive nonsyndromic sen-
orineural hearing loss [20]. In addition to identifying larger-scale
hanges within the genome, dPCR can detect deletions of single
enes associated with disorders like SMA  (SMN1 (survival motor
euron 1)) [21,22] and South East Asian-type (0)-thalassemia
HBA1/HBA2 (˛-globin)) [23]. and Quantiﬁcation 10 (2016) 9–14
dPCR can be used to screen patient samples for intragenic
mutations linked to numerous monogenic disorders. Exam-
ples include veriﬁcation of point mutations in GCM2 (glial
cells missing homolog 2; GCM2(T370M) and GCM2(R367Tfs*))
associated with hypoparathyroidism [24], in MAP3K3 (mitogen-
activated protein kinase kinase kinase 3; MAP3K3(I441M))
with verrucous venus malformation [25], in PIK3CA ( cat-
alytic subunit of phosphatidylinositol-4,5-bisphosphate 3-kinase;
PIK3CA(C420R),  PIK3CA(E542K), PIK3CA(E545K),  PIK3CA(H1047R)
and PIK3CA(H1047L)) with lympathic malformation and Klippel-
Trenaunay syndrome [26], in SMN1 (SMN1(Y272C)) with SMA  [21]
and in GNAS (stimulatory  subunit of G protein, Gs; GNAS(R201C))
with McCune-Albright syndrome [27]. In many cases, the disease-
associated intragenic mutations were initially identiﬁed using
next generation sequencing [24–26]. The disease-associated GNAS
mutation associated with McCune-Albright syndrome could not
be detected in the patient until after death and only in certain
tissues, suggesting somatic mosaicism [27]. With the assistance of
a peptide nucleic acid (PNA) oligomer to lower the detection limit,
Uchiyama et al. [28] can detect low frequency somatic mutations
of GNAQ (G protein  subunit q, Gq; GNAQ(R183Q))  in patients
with Sturge-Weber syndrome, a rare congenital neurocutaneous
multisystem disorder, using droplet dPCR.
In addition to identifying early-onset genetic diseases, dPCR can
detect subclonal mutations in children with various cancers. Using
dPCR, subclonal SETBP1 (SET binding protein 1) point mutations
are detectable in a cohort of patients with juvenile myelomono-
cytic leukemia (JMML) [29]. Standard deep sequencing could not
detect these subclonal point mutations. These somatic SETBP1
mutations were associated with poor prognoses in these patients.
dPCR shows somatic loss of one wild-type NF1 (neuroﬁbromin-1)
allele within a malignant melanoma of a patient with neuroﬁ-
bromatosis type I [30]. Congenital hemangiomas are rare vascular
tumors that develop prenatally as a result of somatic mutations;
ddPCR can detect subclonal mutations in GNAQ (GNAQ(E209L)
and GNAQ(E209P))  and GNA11 (G protein subunit  11,  G11;
GNA11(E209L)) in these tumors [31]. Within tumors, dPCR is a pow-
erful tool to detect subclonal mutations affecting prognosis as well
as loss of heterozygosity.
2.2. Noninvasive detection of genetic alterations in plasma
Cell-free fetal DNA (cffDNA) containing small fragments of fetal
genomic DNA represent a small proportion (about 10%) of the DNA
present in maternal plasma [32]. dPCR can reliably detected very
small quantities of cffDNA in maternal plasma making noninvasive
prenatal diagnosis feasible [12]. Noninvasive prenatal diagnosis of
genetic disorders can be accomplished by comparing either the
copy number of a target chromosome against that of a reference
chromosome (relative chromosome dosage; RCD) or the amount of
the mutant allele relative to the wild-type allele (relative mutation
dosage; RMD). RCD can detect fetal trisomy 21 in maternal plasma
[33]. RCD can also determine the sex of the fetus from cffDNA [34].
As a proof of concept, RMD  detects single nucleotide changes or
small deletions in HBB (ˇ-globin; HbE, (HBB(E26K)) and CD41/42
allele (a 4 nucleotide deletion at codons 41 and 42)) associated
with -thalassemia [35]. RMD  can be used to prenatally diagnose
hemophilia (F8,  coagulation factor VIII; F9,  coagulation factor IX),
sickle cell anemia (HbS, HBB(E6V)) and cystic ﬁbrosis (CFTRF508;
loss of phenylalanine 508 in cystic ﬁbrosis transmembrane con-
ductance regulator (CFTR)) [36–38]. Using massively parallel deep
sequencing, cffDNA can be scanned globally for paternally inher-
ited single nucleotide polymorphisms (SNPs) by relative haplotype
dosage (RHDO) [39]. Lam and colleagues identify mutations in
HBB that are associated with -thalassemia via a targeted RHDO
approach [40].
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One disadvantage of using RCD, RMD  or RHDO for fetal genetic
creening is that a large number of DNA molecules need to be
etected and counted in order to detect increases in dosage.
he use of fetal-speciﬁc markers can enhance the sensitivity
f the genetic screen. For example, epigenetic-genetic chromo-
ome dosage (EGCD) detects trisomy 21 with a hypermethylated
etal DNA marker on chromosome 21 (within the promoter of
LCS; holocarboxylase synthetase)  and reference gene on the Y
hromosome (ZFY, Y-linked zinc ﬁnger protein) [41] or on the
 chromosome (ZFX; X-linked zinc ﬁnger protein) [42]. The use
f rs6636, a paternally-inherited, autosomal SNP within TMED8
transmembrane emp24 protein transport domain containing 8) on
hromosome 14, makes the EGCD assay independent of sex chro-
osomes as reference markers [43]. The epigenetic-genetic dosage
pproach along with targeted Sanger sequencing were used to iden-
ify a point mutation in FGFR3 (ﬁbroblast growth factor receptor 3;
GFR3(G380R)) associated with achondroplasia [44].
Aside from screening for fetal genetic disorders, dPCR can help
dentify maternal genetic factors which could affect the fetus. One
otential complication during pregnancy is hemolytic disease of
he fetus and newborn (HDFN), which is a fetal alloimmune con-
ition resulting in anemia to heart failure (hydrops fetalis) and
eath. The RhD (Rh blood group D) antigen is one factor impli-
ated in HDFN. If a woman without functional RhD carries a fetus
ho inherited a functional RhD from his father (RhD+ pregnancy),
he will develop maternal antibodies against RhD. These maternal
nti-RhD antibodies could cause HDFN in subsequent pregnancies
y crossing the placental barrier and destroying fetal erythrocytes.
tandard genetic screen can identify RhD+ pregnancies in mothers
ompletely lacking RHD but not in those mothers harboring intra-
enic mutations in RHD. dPCR can detect paternally-inherited, fetal
HD in maternal plasma [34,45]. dPCR can accurately detect mater-
al RHD variants like RHD(IVS3 + 1G > A) in the presence of cffDNA
ontaining paternally-inherited RHD [46].
In addition to noninvasive prenatal genetic testing, dPCR can
e used to identify somatic tumor mutations in the plasma of
hildren with cancer. Neuroblastoma-associated mutations in ALK
anaplastic lymphoma receptor tyrosine kinase;  ALK(F1174L) and
LK(R1275Q)) can be detected in cell-free DNA using dPCR [47].
YCN (N-Myc) copy numbers are elevated in cell-free DNA from
he sera of patients with childhood solid tumors [48].
.3. Determination of copy number variations
Larger scale structural variations such as copy number varia-
ions (CNVs) and segmental duplications in the human genome
ave been linked with numerous diseases. aCGH and SNP microar-
ays are currently used to detect CNVs but these techniques are
ostly and have difﬁculty detecting duplications or higher order
ncreases in copy number [49]. dPCR can precisely and reliably
etect CNVs within the genome. SMA  is a genetically homogeneous
arly-onset motor neuron disease with a large variability in pheno-
ype severity. SMN2,  a nearly perfect duplicate gene to SMN1,  copy
umber is inversely related to disease severity in SMA  (reviewed
n Ref. [4]). Droplet and array dPCR can detect a wide range of
MN2 copy numbers, i.e. 0–5 copies, more accurately than other
uantitative PCR techniques at detecting high copy numbers (>4
opies) [21,22]. Higher copy numbers of both BHLHA9 (basic helix-
oop-helix family member A9)  and YWHAE (14-3-3ε) can be detected
y dPCR patients with split-hand malformations associated with
ouble quadruplication in 17p13.3 [50]. In addition to measuring
igher order CNVs, digital PCR can be used to determine mecha-
isms underlying higher order ampliﬁcation of genomic intervals
ike quadruplications within chromosome 17p13.3 in split-hand
alformations [50] and within the PLP1 (proteolipid protein 1) locus
n the X chromosome in Pelizaeus-Merzbacher disease [51]. and Quantiﬁcation 10 (2016) 9–14 11
CNVs associated with diseases having a non-Mendelian inher-
itance pattern, like childhood-onset obesity, can be measured
with dPCR. Fachi and colleagues [52] demonstrate an association
between low AMY1 (salivary amylase) copy number and increased
body mass index (BMI) and risk of obesity. This study used quan-
titative PCR to measure AMY1 copy numbers. A subsequent study
using dPCR fails to validate this inverse relationship between AMY1
copy numbers and obesity risk in a different adult population [53].
However, other studies using dPCR have conﬁrmed this relation-
ship in early-onset obesity. An inverse correlation between AMY1
copy number and risk of early-onset obesity as well as BMI  is found
using dPCR in affected females but not males from Finland [54].
In a cohort of children from Mexico, there is a strong relationship
between high AMY1 copy number and reduced risk of obesity [55].
Future studies will determine if this inverse relationship between
AMY1 copy number and obesity risk is unique to early-onset obe-
sity.
2.4. Measurement of allelic imbalance
Preferential allelic imbalance (PAI) occurs when a disease-
associated heritable SNP is preferentially retained relative to the
wild-type allele. PAI of speciﬁc SNPs have been observed in tumor
DNA from many different cancers including acute lymphoblas-
tic leukemia (ALL), which is the most common childhood cancer.
Tumor PAI can be detected by Sanger sequencing and SNP geno-
typing but neither technique is quantitative. The somatic mutation
allelic ratio test using digital droplet PCR (SMART-ddPCR) quantiﬁes
PAI in ALL tumor DNA [56,57]. SMART-ddPCR uses a similar strategy
to RMD  and RHDO (Section 2.2). This approach has identiﬁed sub-
clonal somatic CNVs using SNPs within CDKN2A (cyclin-dependent
kinase inhibitor 2A) and IKZF1 (Ikaros)  in ALL patients [56] and
found ALL-associated PAI of the CDKN2A(A148T) risk allele [57]. The
CDKN2A and IKZF1 copy numbers measured with SMART-ddPCR
were in agreement with those measured by multiplex ligation-
dependent probe ampliﬁcation (MLPA) [56].
2.5. Detection of disease-associated epigenetic changes
In type I diabetes, the loss of pancreatic  cells is believed to
occur before the clinical presentation of hyperglycemia. It would,
therefore, be desirable to detect  cell death in these individuals
prior to clinical onset. The promoter region of the INS (preproin-
sulin) gene is uniquely unmethylated in  cells [58]. Elevated levels
of unmethylated INS promoter DNA can be detected in the sera of
patients with type I diabetes [58]. Increased levels of unmethylated
INS relative to methylated INS are detected by dPCR in children with
recent onset type I diabetes [59]. Increased unmethylated INS cor-
relates to decreased insulin secretion and also indicates pancreatic
 cell death [60]. When measuring methylated and unmethylated
INS levels independently, both forms of INS DNA  are elevated in
the serum at onset of type I diabetes [61]. The elevations in both
methylated and unmethylated INS DNA gradually diminish as the
disease progressed over time with the rate of unmethylated INS
DNA decline being faster than that for methylated INS DNA [61].
These studies demonstrate the feasibility of dPCR for early detec-
tion of childhood disease with complex genetics.
3. Comparison of digital PCR to other techniques
dPCR is an end-point counting of the number of negative par-
titions. Since dPCR is an absolute quantiﬁcation of a target locus,
there is no need for an externally generated calibration curve. The
independence of dPCR from an external calibration curve gives it
an advantage over qPCR. Another advantage of dPCR is that it is
more tolerant to the inhibitory effects of substances like heparin
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nd SDS (sodium dodecylsulfate) than qPCR [62]. dPCR is more pre-
ise and reproducible than qPCR [63,64]. Both array and droplet
PCR are more accurate at DNA copy number quantiﬁcation than
ther PCR-based approaches [65,66]. When compared against each
ther, array and droplet dPCR are equally precise and accurate.
dPCR is more sensitive than conventional qPCR techniques for
easuring CNVs [67]. For example, dPCR can accurately and reli-
bly measure between 0 and 5 copies of SMN2 in genomic DNA
amples from SMA  patients while other techniques like qPCR have
 narrower range, i.e. 0–3 copies [21,22]. The increased range in
NV detection is due to the linear ampliﬁcation that occurs in dPCR
hich allows for small fold change (i.e. less than 2-fold) differences
o be measured.
In addition to being more sensitive at measuring single unit
hanges in copy number, dPCR can detect low abundance of a target
ocus within a heterogeneous mix  of DNA. The increased sensitivity
f dPCR at detecting low levels of target DNA within a complex mix-
ure of DNA has been demonstrated by detecting subclonal SETBP1
oint mutations in patients with JMML,  a low frequency somatic
NAQ(R183Q) mutation in patients with Sturge-Weber syndrome
28] and a GNAS1(R201C) mutation within some tissues of McCune-
lbright syndrome post-mortem case [27,29]. In cffDNA, dPCR is
ore sensitive than standard qPCR in detecting fetal RHD as well
s the sex of the fetus in maternal plasma [34,45]. dPCR, therefore,
s better capable of analyzing complex mixtures of DNA to detect
are locus events than qPCR.
Variability in the partition volume can affect the accuracy of the
arget locus quantiﬁcation in dPCR, usually resulting in an underes-
imation [10,14,65,66]. This variability tends to be a greater concern
or droplet dPCR than for array dPCR since the partition size within
he nanoﬂuidic chamber is constant. There may  be, however, small
ifferences in partition size between different batches of nanoﬂu-
dic chambers which can contribute to error. In a recent study, the
ncertainty associated with variable partition volume was  shown
o be very low, between 0.7% and 2.9% depending on the platform
65]. The error resulting from this variability may  be small relative
o other potential sources of error that are not unique to dPCR, like
ample processing and loading.
dPCR assumes that there is a random distribution of template
NA throughout the partitions. In some cases, copies of the target
NA are arranged in close proximity to each other on the template
NA; in order words, two (or more) copies of the target DNA will
lways be in a single partition. As a result, there will be an underes-
imation of the measured copy number [67,68]. This limitation can
e circumvented by disrupting the template DNA biochemically
ith a restriction endonuclease that cleaves between the copies of
he target DNA or mechanically using DNA shearing [22].
When performing dPCR, the reaction mix  must ﬁrst be par-
itioned by either nanoﬂuidic chambers or nanodroplets. After
he dPCR run is completed, the partitions need to be read ﬂu-
rimetrically using a separate apparatus. At present, dPCR is,
herefore, more labor intensive than qPCR and requires special-
zed equipment. This post-PCR handling of samples in dPCR is one
isadvantage over qPCR, however, future developments in sam-
le automation will minimize the impact of post-PCR handling on
PCR. Additionally, air bubbles can be introduced during the load-
ng of the samples which can adversely affect the readout. New
PCR technologies such as the use of a centrifugal microﬂuidic
isk are being developed to circumvent some of these limitations
69]. Despite these limitations, dPCR does have many advantages,
ighlighted in this section, over conventional qPCR.
Next generation sequencing (NGS) approaches – like whole
xome (WES) and whole genome (WGS) sequencing – are increas-
ngly being used to diagnose genetic disorders in children [3,70].
GS is particularly useful in rapidly identifying a molecular diag-
osis for a monogenic disease whose genetic basis has not yet and Quantiﬁcation 10 (2016) 9–14
been ascertained. This rapid testing would be particularly beneﬁcial
for neonatal onset disorders [71]. Although these next generation
sequencing approach offer some advantages over standard diag-
nostic procedures including dPCR, WES  and WGS  require highly
specialized equipment and detailed bioinformatic analysis of a
large set of sequencing data. Deep sequencing can also miss iden-
tifying subclonal SETBP1 point mutations in a JMML which can be
detected by dPCR [29]. NGS approaches are better suited for genetic
discovery but dPCR has advantages over NGS in the detection of
known mutations.
Another advantage of NGS is that it can also analyze multiple
target genes at the same time making it a remarkable platform
for multiplexing. dPCR can some multiplexing capability in that,
to date, up to ﬁve different target regions can be detected at the
same time using two  different ﬂuorophores [21]. The multiplexing
capacity of dPCR can be further increased in the future by increas-
ing the number of ﬂuorophores, designing better probes which can
produce larger differential signals and using one-to-one droplet
fusions containing the template DNA and different probes [13,21].
Before dPCR approaches can be regularly used for molecular
diagnostics, many of these aforementioned considerations need
to be adequately addressed [68,72]. The fact that the primers and
probes designed for conventional qPCR-based diagnostic tests can
also be easily used by dPCR should facilitate its routine use in diag-
nostics. The relatively easy readout used by dPCR make it more
suitable for a broader group of individuals as it does not require
specialized skills. The dPCR readout is also amenable to higher
throughput and automated formats. These newer formats should
make dPCR more cost effective and reduce the amount of time it
takes to complete the diagnostic assay.
4. Conclusions
In summary, dPCR provides a way  to accurately and reliably
detect genomic alterations including gene deletions and point
mutations, or single nucleotide polymorphisms. Because of its
sensitivity, dPCR can detect a speciﬁc target locus at a very low con-
centration within a genomic DNA mixture, making this technique
particularly amenable to track somatic subclonal mutations as well
as cffDNA. dPCR has a large dynamic range of detection which per-
mits the accurate quantiﬁcation of CNVs in genes associated with
pediatric diseases as well as in their modiﬁers. Because of these
advantages, dPCR shows great prognostic – and potentially diag-
nostic – value in caring for and ultimately treating children with
genetic diseases.
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